Alterations of the human 16p11.2 chromosomal region lead to a variety of cognitive disorders, including autism. Credit: Pasieka/Science Source
Several genetic disorders cause intellectual disability and autism. Historically, these genetic brain diseases were viewed as untreatable. However, in recent years neuroscientists have shown in animal models that it is possible to reverse the debilitating effects of these gene mutations. But the question remained whether different gene mutations disrupt common physiological processes. If this were the case, a treatment developed for one genetic cause of autism and intellectual disability might be useful for many others.
In a paper published today in the online edition of Nature Neuroscience, a research team led by Mark Bear, the Picower Professor of Neuroscience in MIT's Picower Institute for Learning and Memory, showed that two very different genetic causes of autism and intellectual disability disrupt protein synthesis at synapses, and that a treatment developed for one disease produced a cognitive benefit in the other. The research was performed by postdoc and lead author Di Tian, graduate student Laura Stoppel, and research scientist Arnold Heynen, in collaboration with scientists at Cold Spring Harbor Laboratory and Roche Pharmaceuticals.
Researching the role of fragile X syndrome
One heritable cause of intellectual disability and autism is fragile X syndrome, which arises when a single gene on the X chromosome, called FMR1, is turned off during brain development. Fragile X is rare, affecting one in about 4,000 individuals. In previous studies using mouse models of fragile X, Bear and others discovered that the loss of this gene results in exaggerated protein synthesis at synapses, the specialized sites of communication between neurons.
Of particular interest, they found that this protein synthesis was stimulated by the neurotransmitter glutamate, downstream of a glutamate receptor called mGluR5. This insight led to the idea, called the mGluR theory, that too much protein synthesis downstream of mGluR5 activation gives rise to many of the psychiatric and neurological symptoms of fragile X. Bear's lab tested this idea in mice, and found that inhibiting mGluR5 restored balanced protein synthesis and reversed many defects in the animal models.
Different genes, same consequences
Another cause of autism and intellectual disability is the loss of a series of genes on human chromosome 16, called a 16p11.2 microdeletion. Some of the 27 affected genes play a role in protein synthesis regulation, leading Bear and colleagues to wonder if 16p11.2 microdeletion syndrome and fragile X syndrome affect synapses in the same way. To address this question, the researchers used a mouse model of 16p11.2 microdeletion, created by Alea Mills at Cold Spring Harbor Laboratory.
Using electrophysiological, biochemical, and behavioral analyses, the MIT team compared this 16p11.2 mouse with what they already had established in the fragile X mouse. Synaptic protein synthesis was indeed disrupted in the hippocampus, a part of the brain important for memory formation. Moreover, when they tested memory in these mice, they discovered a severe deficit, similar to fragile X.
Restoring brain function after disease onset
These findings encouraged the MIT researchers to attempt to improve memory function in the 16p11.2 mice with the same approach that has worked in fragile X mice. Treatment with an mGluR5 inhibitor, provided by a team of scientists at Roche led by Lothar Lindemann, substantially improved cognition in these mice. Of particular importance, this benefit was achieved with one month of treatment that began well after birth. The implication, according to Bear, is that "some cognitive aspects of this disease, previously believed to be an intractable consequence of altered early brain development, might instead arise from ongoing alterations in synaptic signaling that can be corrected by drugs."
Current research indicates that well over 100 distinct gene mutations can manifest as intellectual disability and autism. The current findings are heartening, as they indicate not only that drug therapies might be effective to improve cognition and behavior in affected individuals, but also that a treatment developed for one genetic cause might apply more broadly to many others.
Explore further: Fragile X study offers hope of new autism treatment
More information: "Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion." Nature Neuroscience (2015) DOI: 10.1038/nn.3911
This story is republished courtesy of MIT News (http://ift.tt/ABbm9r), a popular site that covers news about MIT research, innovation and teaching.
Medical Xpress on facebook
Related Stories
Neuroscientists find that two rare autism-related disorders are caused by opposing malfunctions in the brain
Nov 24, 2011
(Medical Xpress) -- Most cases of autism are not caused by a single genetic mutation. However, several disorders with autism-like symptoms, including the rare Fragile X syndrome, can be traced to a specific mutation. Several ...
Neurologists finds potential route to better treatments for Fragile X, autism
Oct 23, 2013
When you experience something, neurons in the brain send chemical signals called neurotransmitters across synapses to receptors on other neurons. How well that process unfolds determines how you comprehend the experience ...
Fragile X study offers hope of new autism treatment
Nov 27, 2014
People affected by a common inherited form of autism could be helped by a drug that is being tested as a treatment for cancer.
Mutated gene linked to both autism and intellectual disability
Jul 24, 2014
Autism spectrum disorder and intellectual disability often occur together and may even share similar genetic causes. Researchers reporting in the Cell Press journal Cell Reports have now linked mutations in a particular gene t ...
Fragile X and Down syndromes share signalling pathway for intellectual disability
Aug 03, 2012
Intellectual disability due to Fragile X and Down syndromes involves similar molecular pathways report researchers in The EMBO Journal. The two disorders share disturbances in the molecular events that regula ...
Recommended for you
People watching: Different brain pathways responsible for person, movement recognition
15 hours ago
Each time you see a person that you know, your brain seemingly effortlessly and immediately recognizes that person by his or her face and body. Just as easily, your brain understands a person's movements, ...
Experience of pain relies on multiple brain pathways, not just one
18 hours ago
People's mindsets can affect their experience of pain. For example, a soldier in battle or an athlete in competition may report that an injury did not feel especially painful in the heat of the moment. But ...
Imaging study finds first evidence of neuroinflammation in brains of chronic pain patients
18 hours ago
A new study from Massachusetts General Hospital (MGH) investigators has found, for the first time, evidence of neuroinflammation in key regions of the brains of patients with chronic pain. By showing that ...
New research on what the nose 'knows' reveals an unexpected simplicity
19 hours ago
What the nose knows is quite amazing, when you think about it. The moment you encounter an awful odor - spoiled milk, say, or the scent of skunk - you reflexively recoil in disgust. Often, too, you take action, ...
Mortality risks after carotid artery stenting in medicare beneficiaries
19 hours ago
Medicare beneficiaries who underwent carotid artery stenting (CAS) had a 32 percent mortality rate during an average two-year follow-up, suggesting the benefits of CAS may be limited for some patients, according to a study ...
Research team identifies important control mechanisms for walking
20 hours ago
Even after complete spinal paralysis, the human spinal cord is able to trigger activity in the leg muscles using electrical pulses from an implanted stimulator. This has already been demonstrated in earlier ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Alterations of the human 16p11.2 chromosomal region lead to a variety of cognitive disorders, including autism. Credit: Pasieka/Science Source
Several genetic disorders cause intellectual disability and autism. Historically, these genetic brain diseases were viewed as untreatable. However, in recent years neuroscientists have shown in animal models that it is possible to reverse the debilitating effects of these gene mutations. But the question remained whether different gene mutations disrupt common physiological processes. If this were the case, a treatment developed for one genetic cause of autism and intellectual disability might be useful for many others.
In a paper published today in the online edition of Nature Neuroscience, a research team led by Mark Bear, the Picower Professor of Neuroscience in MIT's Picower Institute for Learning and Memory, showed that two very different genetic causes of autism and intellectual disability disrupt protein synthesis at synapses, and that a treatment developed for one disease produced a cognitive benefit in the other. The research was performed by postdoc and lead author Di Tian, graduate student Laura Stoppel, and research scientist Arnold Heynen, in collaboration with scientists at Cold Spring Harbor Laboratory and Roche Pharmaceuticals.
Researching the role of fragile X syndrome
One heritable cause of intellectual disability and autism is fragile X syndrome, which arises when a single gene on the X chromosome, called FMR1, is turned off during brain development. Fragile X is rare, affecting one in about 4,000 individuals. In previous studies using mouse models of fragile X, Bear and others discovered that the loss of this gene results in exaggerated protein synthesis at synapses, the specialized sites of communication between neurons.
Of particular interest, they found that this protein synthesis was stimulated by the neurotransmitter glutamate, downstream of a glutamate receptor called mGluR5. This insight led to the idea, called the mGluR theory, that too much protein synthesis downstream of mGluR5 activation gives rise to many of the psychiatric and neurological symptoms of fragile X. Bear's lab tested this idea in mice, and found that inhibiting mGluR5 restored balanced protein synthesis and reversed many defects in the animal models.
Different genes, same consequences
Another cause of autism and intellectual disability is the loss of a series of genes on human chromosome 16, called a 16p11.2 microdeletion. Some of the 27 affected genes play a role in protein synthesis regulation, leading Bear and colleagues to wonder if 16p11.2 microdeletion syndrome and fragile X syndrome affect synapses in the same way. To address this question, the researchers used a mouse model of 16p11.2 microdeletion, created by Alea Mills at Cold Spring Harbor Laboratory.
Using electrophysiological, biochemical, and behavioral analyses, the MIT team compared this 16p11.2 mouse with what they already had established in the fragile X mouse. Synaptic protein synthesis was indeed disrupted in the hippocampus, a part of the brain important for memory formation. Moreover, when they tested memory in these mice, they discovered a severe deficit, similar to fragile X.
Restoring brain function after disease onset
These findings encouraged the MIT researchers to attempt to improve memory function in the 16p11.2 mice with the same approach that has worked in fragile X mice. Treatment with an mGluR5 inhibitor, provided by a team of scientists at Roche led by Lothar Lindemann, substantially improved cognition in these mice. Of particular importance, this benefit was achieved with one month of treatment that began well after birth. The implication, according to Bear, is that "some cognitive aspects of this disease, previously believed to be an intractable consequence of altered early brain development, might instead arise from ongoing alterations in synaptic signaling that can be corrected by drugs."
Current research indicates that well over 100 distinct gene mutations can manifest as intellectual disability and autism. The current findings are heartening, as they indicate not only that drug therapies might be effective to improve cognition and behavior in affected individuals, but also that a treatment developed for one genetic cause might apply more broadly to many others.
Explore further: Fragile X study offers hope of new autism treatment
More information: "Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion." Nature Neuroscience (2015) DOI: 10.1038/nn.3911
This story is republished courtesy of MIT News (http://ift.tt/ABbm9r), a popular site that covers news about MIT research, innovation and teaching.
Medical Xpress on facebook
Related Stories
Neuroscientists find that two rare autism-related disorders are caused by opposing malfunctions in the brain
Nov 24, 2011
(Medical Xpress) -- Most cases of autism are not caused by a single genetic mutation. However, several disorders with autism-like symptoms, including the rare Fragile X syndrome, can be traced to a specific mutation. Several ...
Neurologists finds potential route to better treatments for Fragile X, autism
Oct 23, 2013
When you experience something, neurons in the brain send chemical signals called neurotransmitters across synapses to receptors on other neurons. How well that process unfolds determines how you comprehend the experience ...
Fragile X study offers hope of new autism treatment
Nov 27, 2014
People affected by a common inherited form of autism could be helped by a drug that is being tested as a treatment for cancer.
Mutated gene linked to both autism and intellectual disability
Jul 24, 2014
Autism spectrum disorder and intellectual disability often occur together and may even share similar genetic causes. Researchers reporting in the Cell Press journal Cell Reports have now linked mutations in a particular gene t ...
Fragile X and Down syndromes share signalling pathway for intellectual disability
Aug 03, 2012
Intellectual disability due to Fragile X and Down syndromes involves similar molecular pathways report researchers in The EMBO Journal. The two disorders share disturbances in the molecular events that regula ...
Recommended for you
People watching: Different brain pathways responsible for person, movement recognition
15 hours ago
Each time you see a person that you know, your brain seemingly effortlessly and immediately recognizes that person by his or her face and body. Just as easily, your brain understands a person's movements, ...
Experience of pain relies on multiple brain pathways, not just one
18 hours ago
People's mindsets can affect their experience of pain. For example, a soldier in battle or an athlete in competition may report that an injury did not feel especially painful in the heat of the moment. But ...
Imaging study finds first evidence of neuroinflammation in brains of chronic pain patients
18 hours ago
A new study from Massachusetts General Hospital (MGH) investigators has found, for the first time, evidence of neuroinflammation in key regions of the brains of patients with chronic pain. By showing that ...
New research on what the nose 'knows' reveals an unexpected simplicity
19 hours ago
What the nose knows is quite amazing, when you think about it. The moment you encounter an awful odor - spoiled milk, say, or the scent of skunk - you reflexively recoil in disgust. Often, too, you take action, ...
Mortality risks after carotid artery stenting in medicare beneficiaries
19 hours ago
Medicare beneficiaries who underwent carotid artery stenting (CAS) had a 32 percent mortality rate during an average two-year follow-up, suggesting the benefits of CAS may be limited for some patients, according to a study ...
Research team identifies important control mechanisms for walking
20 hours ago
Even after complete spinal paralysis, the human spinal cord is able to trigger activity in the leg muscles using electrical pulses from an implanted stimulator. This has already been demonstrated in earlier ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment